The New England Journal of Medicine
10 Shattuck Street
313 articles with The New England Journal of Medicine
The New England Journal of Medicine published detailed results from a Phase 3 trial evaluating nirsevimab, the first investigational long-acting antibody designed to protect all infants across the respiratory syncytial virus season with a single dose.
New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A
BIVV001 is the first investigational factor VIII therapy independent of von Willebrand factor and has the potential to transform replacement therapy for people with haemophilia A
Hospitals participating in the 340B drug pricing program are reimbursed for physician-administered medicines at a rate that is on average three times what they paid to acquire the medicine, according to a new analysis conducted by Milliman and commissioned by the Pharmaceutical Research and Manufacturers of America.
Another scientific paper has been retracted by the New England Journal of Medicine. The noted journal said it retracted a paper on evidence of human lung stem cells following an investigation that revealed images used in the article had been manipulated.
NEJM Group announced Thursday that Jeffrey M. Drazen, M.D., Editor-in-Chief of the New England Journal of Medicine, will retire within the next year.
John Theurer Cancer Center Release: Critical Hodgkin's Lymphoma Cancer Study Published in the New England Journal of Medicine
John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center participated in a pivotal clinical trial for Hodgkin's Lymphoma.
John Theurer Cancer Center Release: Pivotal CAR-T Therapy Cancer Study Published in the New England Journal of Medicine
John Theurer Cancer Center at Hackensack University Medical Center is the only New Jersey center that participated in a pivotal clinical trial of a groundbreaking cancer treatment, CAR-T Cell therapy, which genetically modifies a patient's immune system to attack cancer cells.
Pfizer's Phase III TRUMENBA (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity
These studies met all five co-primary immunogenicity endpoints against a panel of diverse test strains.
The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy.
The New England Journal of Medicine Publishes First Phase III Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
SPINRAZA demonstrated a favorable benefit-risk profile.
AveXis Announces New England Journal of Medicine Publication of Phase I Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1
The NEJM publication provides detailed data as of August 7, 2017, from the Phase 1, open-label, dose-escalating study, designed to evaluate the safety and tolerability of AVXS-101 in patients with SMA Type 1.
Nobles Medical Technology II Release: NobleStitch EL Closure Data Presented At CSI UCSF Congress Compares Published RESPECT And CLOSURE PFO Data In The New England Journal of Medicine To NobleStitch
Heartstitch GmbH Announces Noblestitch EL Closure Data Compared To Published PFO Clinical Trials "RESPECT" And "CLOSURE" In The New England Journal of Medicine
Inovio Pharma’s Positive Zika Vaccine Clinical Study Data Published In The New England Journal of Medicine
Lexicon Pharma Release: The New England Journal of Medicine Publishes Data From Phase III InTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
Amgen Release: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal of Medicine
Juno And The New England Journal of Medicine Release: Anti-CD19 CAR T Cells In CNS Diffuse Large-B-Cell Lymphoma
Amgen Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine
Positive Phase III Results Of Genentech’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online